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A positive correlation of serum homocysteine with leptin
in maintenance hemodialysis patients
Hamid Nasri
A b s t r a c t
Introduction: Serum leptin is cleared principally by the kidneys and serum leptin
concentrations are increased in patients with chronic renal failure and those
undergoing a maintenance dialysis. Mild-to-moderate elevations in plasma total
homocysteine (Hcy) levels are also observed in the great majority of patients
with end-stage renal disease who are undergoing a dialysis. A paradoxically
inverse association between higher serum leptin and improved markers of the
nutritional status was shown. Based on the above mentioned data regarding the
associations of homocysteine and leptin with the nutritional status, we tested
the hypothesis that the concentration of serum homocysteine and leptin in
hemodialysis patients may have an association.
Material and methods: In a cross-sectional analysis on 36 (F=15, M=21) stable
hemodialysis (HD) patients, consisting of 25 non-diabetic HD patients and 11
diabetics, serum homocysteine and serum leptin were measured.
Results: In this study a significant positive correlation of serum leptin with
homocysteine and a significant positive correlation of homocysteine with the
body mass index (BMI) and also a significant positive correlation of leptin with
BMI were found. 
Conclusions: The positive correlations of serum homocysteine with leptin and
also with BMI show its good correlation with the nutritional status of regular
hemodialysis patients.
Key words: leptin, homocysteine, maintenance hemodialysis patients, body mass
index, malnutrition-inflammation cachexia syndrome.
Introduction
Homocysteine (Hcy) is a sulphur amino acid formed from methionine
during transmethylation, and is either salvaged to methionine by a folate-
and cobalamin-dependent re-methylation reaction or directed toward
degradation by the vitamin B6-dependent enzyme cystathionine 
β-synthase [1, 2]. Large studies have demonstrated that moderate
hyperhomocysteinaemia is an independent risk factor for premature
atherosclerosis and cardiovascular disease [3]. Mild-to-moderate elevations
in plasma total homocysteine (Hcy) levels are observed in the great majority
(>85%) of patients with end-stage renal disease who are undergoing a
maintenance dialysis [3, 4]. In maintenance hemodialysis patients (MHDPs),
the association between Hcy and clinical outcome is inconsistent and even
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paradoxical. Some studies have shown a poor
outcome in MHD patients with hyperhomocyste-
inemia. Recent studies have suggested that 
a decreased, not an increased, Hcy concentration is
related to a higher prevalence of cardiovascular
disease and poor outcome in these individuals 
[4-6]. Indeed plasma levels of total homocysteine
are influenced by the nutritional status in patients
with chronic kidney disease [7, 8]. More recent
studies showed that an increased level of total
plasma homocysteine is a risk factor for poor
cardiovascular outcome in the general population.
However, a decreased, rather than an increased, Hcy
concentration may predict poor outcome in
maintenance hemodialysis (MHD) patients, 
a phenomenon referred to as reverse epidemiology
[9]. This seems to be due to the association between
a low Hcy and protein-energy malnutrition, which
is per se a known risk factor for poor clinical
outcome in dialysis patients [6, 10]. This recently
described paradoxical association between tHcy and
clinical outcome in dialysis patients has now been
referred to as a possible component of the reversal
of the cardiovascular risks [11-13]. It is believed that
both inflammation and protein-energy malnutrition,
each independently or together as the “malnutri-
tion-inflammation complex syndrome” are
responsible for this condition [13-17]. Studies have
demonstrated that leptin is cleared principally by
the kidney and serum leptin concentrations are
increased in patients with chronic renal failure and
those undergoing a maintenance dialysis [18, 19].
Studies in maintenance dialysis patients also
suggest a paradoxically inverse association between
higher serum leptin and improved markers of the
nutritional status [20, 21]. Based on the above
mentioned data regarding the associations of
homocysteine and leptin with the nutritional status,
we tested the hypothesis that a high concentration
of serum homocysteine and leptin in hemodialysis
patients may have a correlation with each other.
Therefore in a group of hemodialysis patients
containing diabetics and non-diabetics, we
considered this correlation to better find the
association of homocysteine and leptin with various
nutritional parameters in MHDPs.
Material and methods 
Patients 
This cross-sectional study was conducted on
patients with end-stage renal disease (ESRD), who
were undergoing a maintenance hemodialysis
treatment with acetate basis dialysate and
polysulfone membranes. According to the severity
of secondary hyperparathyroidism, each patient
being treated for secondary hyperparathyroidism
was given oral active vitamin D3 (Calcitriol; Rocaltrol)
(Roche Hexagon; Roche Laboratories Inc., New Jersey,
USA), calcium carbonate capsule, and Rena-Gel
(sevelamer; Genzyme Europe B.V.; United
Kingdom/Ireland) tablets at various doses. According
to the severity of anemia, patients were prescribed
intravenous iron therapy with Iron Sucrose (Venofer)
(International Inc., St. Gallen/Switzerland) at various
doses after each dialysis session. All patients
received treatments of 6 mg folic acid daily, 500 mg
Acetyl-L-Carnitine (Jarrow Formulas, Inc.™, Los
Angeles, CA) daily, oral vitamin B-complex tablets
daily, and 2,000 U intravenous Eprex (recombinant
human erythropoietin; Janssen-Cilag; CILAG-AG
International 6300 Zug/Switzerland) after each
dialysis session. Exclusion criteria were active or
chronic infection and using NSAID or ACE inhibitor
drugs. The study was done in the hemodialysis
section of the Hajar Medical Educational &
Therapeutic Center of Shahrekord University of
Medical Sciences in Shahrekord of Iran.
Laboratory methods
Serum homocysteine (total) and serum leptin were
measured as follows. Blood samples were drawn after
an overnight fast. All blood samples were centrifuged
within 15 min of venepuncture, and were measured
by the enzyme-linked immunosorbent assay (ELISA)
method using DRG kits (DRG Diagnostics, Berlin,
Germany). Serum leptin has a normal range of 3.84
(±1.79) for males and 7.36 (±3.73) ng/ml for females
and serum total homocysteine has a normal range
of 25-125 μmol/L. Also peripheral venous blood
samples were collected after an overnight fast, for
the hemoglobin level (using Sysmex-KX-21N Cell
counter; Sysmex Corporation; Mundelein, Illinois,
Sysmex America, Inc.) and a biochemical analysis
including serum predialysis creatinine (Creat), post
and predialysis blood urea nitrogen (BUN), albumin
(Alb) as well as serum C-reactive protein (CRP). For
patients levels of serum ferritin by the radio immune
assay method (RIA), were measured using standard
kits. Body mass index (BMI) calculated using the
standard formula (postdialyzed weight in
kilograms/height in square meters; kg/m2). For the
efficacy of hemodialysis the urea reduction rate
(URR) was calculated from pre- and post-blood urea
nitrogen (BUN) data. Duration and the amount of
sessions of hemodialysis treatment were calculated
from the patients’ records. The duration of each
hemodialysis session was 4 hours.
Statistical analysis
Results are expressed as the mean ±SD and
median values. The comparison between the groups
was done using the Student’s t-test. Statistical
correlations were assessed using the partial
correlation test. The statistical analysis was
performed on total hemodialysis (HD), females,
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Table I. Patients' data
Total patients Minimum Maximum Mean ±SD Median
N=36
Age [years] 27 75 53±15.8 43
DH* [months] 6 24 14.5±6 36
Dialysis sessions 54 216 123±54 156
URR [%] 39 75 53.5±9.8 57.5
Leptin [ng/ml] 0.10 73 9.4±14 5.75
Hgb [g/dl] 5 13 9±2 9
Homocysteine [μmol/L] 1.2 12.8 5±2.4 4.5
Ferritin [ng/dl] 35 1250 519±299 426
Alb [g/dl] 2.4 4.8 3.8±0.5 3.95
CRP [mg/l] 3 40 8.7±6.7 8
BMI [kg/m2] 16 34 21.8±4.5 21.5
Non-diabetic patients Minimum Maximum Mean±SD Median
N=25
Age [years] 16 80 44±17 41
DH* [months] 2 156 40±40.8 22
Dialysis sessions 36 1584 370±452 156
URR [%] 60 76 61±7.5 60
Leptin [ng/ml] 0.10 52 7.6±10.5 4
Hgb [g/dl] 5 12 8.5±2 9
Homocysteine [μmol/L] 1.2 9.7 5±2 5.6
Ferritin [ng/dl] 170 1250 576±282 483
Alb [g/dl] 2.4 4.7 3.8±0.5 4
CRP [mg/l] 2 20 7.4±3.8 6
BMI [kg/m2] 16 33 21±4.6 19
Diabetic patients Minimum Maximum Mean±SD Median
N=11
Age [years] 27 75 53±15.8 55
DH* [months] 6 24 14.5±6 12
Dialysis  sessions 54 216 123±54 108
URR [%] 39 75 53.5±9.8 54
Leptin [ng/ml] 0.2 73 13.6±20 8.3
Hgb [g/dl] 0.5 13 10±2 10
Homocysteine [μmol/L] 2.8 12.8 5±3 4.3
Ferritin [ng/dl] 35 1000 388±308 278
Alb [g/dl] 3 4.8 3.8±0.5 3.9
CRP [mg/l] 4 40 12±10 10
BMI [kg/m2] 20 34 23±4 23
*duration of hemodialysis
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males, diabetics and non diabetics populations
separately. All statistical analyses were performed
using SPSS (version 11.5.00) (SPSS Inc., Chicago, IL).
The statistical significance was determined at a p-
value below than 0.05.
Results
The study patients were 36 (F=15, M=21),
consisting of 25 (F=11, M=14) non-diabetic HD
patients and 11 (F=4, M=7) diabetic HD patients.
Table I shows the patients’ data. The mean patient’s
age was 53 (±15.8) years. The value of serum
homocysteine of all HD patients was 5 (±2.4) μmol/L.
The values of serum Hcy of diabetic and nondiabetic-
dialysis patients were 5 (±3) and 5 (±2) μmol/L,
respectively. The value of serum leptin of all HD
patients was 9.4 (±14) ng/ml. The values of serum
leptin of diabetic and non-diabetic-dialysis patients
were 13.6 (±20) and 7.6 (±10.5) ng/ml, respectively.
There were no significant differences of serum leptin
between diabetic and non-diabetics or male and
female HD patients also no significant differences
of serum homocysteine between diabetic and non-
-diabetics or male and female HD patients were
found. In all HD patients a significant positive
correlation of serum leptin with serum homocysteine
(r=0.34, p=0.042; Figure 1) (adjusted for age) was
seen. In this group also a significant positive
correlation of serum homocysteine with BMI (r=0.35,
p=0.039; Figure 2) (adjusted for duration of dialysis)
was seen, too. Moreover, in this group a significant
positive correlation of serum leptin with BMI (r=0.58,
p<0.001; Figure 3) (adjusted for age) was seen. 
Discussion
In this study a significant positive correlation of
serum leptin with serum homocysteine and a
significant positive correlation of serum
homocysteine with BMI were seen. Also a significant
positive correlation of serum leptin with BMI was
found too. To examine the association between the
homocysteine level and markers of malnutrition-
-inflammation complex syndrome and 12-months
prospective hospitalization and mortality in 367
MHDPs, aged 54.5±14.7 years, Kalantar-Zadeh et al.
found weak to moderate but statistically significant
correlations of hyperhomocysteinemia with some
laboratory markers of nutrition (serum albumin,
prealbumin, creatinine, and urea nitrogen) but no
significant correlation with serum C-reactive protein
existed [10]. They found that the hospitalization rates
were significantly higher in patients with lower Hcy
levels and mortality rate in the lowest Hcy quartile
was significantly higher compared with other three
quartiles. They concluded that Hcy may be a more
exclusive nutritional marker in MHD patients with
no association with inflammatory measures [10]. In
a study conducted by Suliman et al. on a cohort of
250 patients with chronic kidney disease (CKD)
which starting a renal replacement therapy to assess
the overall mortality in relation to basal tHcy level
followed the patients during a 4-year period. They
found that ninety-three patients (37%) with signs of
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Figure 1. A significant positive correlation of serum
leptin with serum homocysteine
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Figure 2. A significant positive correlation of serum
homocysteine with BMI 
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Figure 3. A significant positive correlation of serum
Leptin with BMI
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inflammation (CRP >or =1 mg/dL) had significantly
lower levels of tHcy and serum Alb than 157
noninflamed patients. Homocysteine levels correlated
positively with serum Alb levels and negatively with
CRP levels and other inflammation markers. They
showed that the presence of both inflammation and
malnutrition was associated with lower homocysteine
levels than when malnutrition was present without
inflammation. They also showed that that serum Alb
and CRP levels were independently associated with
Hcy levels after adjustment for other variables. The
serum Hcy level was significantly greater in survivors
than nonsurvivors, and a greater Hcy level was
associated with better survival, moreover, they
concluded that plasma Hcy level was lower in patients
with inflammation and inflammation may contribute
to the reverse association between the Hcy level and
mortality in patients with CKD starting a renal
replacement therapy [8]. Recent studies in maintenance
dialysis patients suggest a paradoxically inverse
association between higher serum leptin and improved
markers of nutritional status [20, 21], a finding that is
consistent with the theory of reverse epidemiology [16].
Indeed, leptin, similar to serum albumin, has been
reported to be a negative acute phase reactant in end-
stage renal failure patients [21, 22]. 
Conclusions
The positive correlations of serum homocysteine
with leptin and also with BMI show its well
association with nutritional status of regular
hemodialysis patients.
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